NDC 80425-0078-02 - Cyclobenzaprine HCL
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 80425-0078
- Requested NDC
- 80425-0078-02
- Package NDCs from labels
- 80425-0078-3, 80425-0078-2, 80425-0078-1, 80425-0078-4, 80425-0078-02
- Manufacturer
- Advanced Rx of Tennessee, LLC
- Effective date
- 2024-12-31
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Cyclobenzaprine HCL - Advanced Rx of Tennessee, LLC | Advanced Rx of Tennessee, LLC | 2024-12-31 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 80425-0078-1 | Cyclobenzaprine HCL | 30 in 1 BOTTLE | TABLET, FILM COATED | 30 | 8 | |
| 80425-0078-2 | Cyclobenzaprine HCL | 60 in 1 BOTTLE | TABLET, FILM COATED | 60 | 8 | |
| 80425-0078-3 | Cyclobenzaprine HCL | 90 in 1 BOTTLE | TABLET, FILM COATED | 90 | 8 | |
| 80425-0078-4 | Cyclobenzaprine HCL | 120 in 1 BOTTLE | TABLET, FILM COATED | 120 | 8 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 80425-0078 | CYCLOBENZAPRINE HCL TABLET, FILM COATED [ADVANCED RX OF TENNESSEE, LLC] | 8 | Current NDC, Legacy NDC, 4 package rows | 20250101_b062cb80-79a9-c5d8-e053-2a95a90aecfc.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 80425-0078-1 | EA - Each | 80425-0078 | faeb789a-f658-40d2-955f-90302eaac6ad | 1 | 2023-03-13 |
| 80425-0078-2 | EA - Each | 80425-0078 | 2ca4c93d-9118-4778-b285-ba468434b899 | 1 | 2023-03-13 |
| 80425-0078-3 | EA - Each | 80425-0078 | ec0d8c5e-bb09-435d-bc04-8b71fbc307a5 | 1 | 2023-03-13 |
| 80425-0078-4 | EA - Each | 80425-0078 | 9852b7d2-cc36-43de-a98e-4ab927596053 | 1 | 2023-03-13 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | REMEDYREPACK INC. | 5d536e88-62be-45bd-bd09-0efc53fe12b9 | 2026-09-09 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Sportpharm LLC | 71185d15-3fd7-42b7-83a6-8357e3aaef43 | 2026-09-05 | Warnings, Adverse reactions | 828299 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | REMEDYREPACK INC. | 34e57aff-dc4b-4631-9d57-31020244835d | 2026-09-03 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | REMEDYREPACK INC. | 37056cab-953e-43ba-9b4c-163a739a52f7 | 2026-09-02 | Warnings, Adverse reactions | 828299 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | REMEDYREPACK INC. | 30e61110-5bc8-4134-8456-538558479735 | 2026-09-01 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | REMEDYREPACK INC. | ba659e1a-0091-45f6-b418-f4f36c9a2c79 | 2026-08-31 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | REMEDYREPACK INC. | 3175d24d-e8a0-4f14-bed9-a60ad59ac7e7 | 2026-08-28 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Direct_Rx | 903e3a5a-7c58-b70d-e053-2a95a90a6f9d | 2026-08-27 | Warnings, Adverse reactions | ANDA078722 828299 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | REMEDYREPACK INC. | e4ed7ad2-cf58-4fdb-bc8c-d89f23b01210 | 2026-08-17 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Unit Dose Solutions, Inc. | 53bef1ab-55c0-cc52-e063-6394a90a12b3 | 2026-08-17 | Warnings, Adverse reactions | 0VE05JYS2P |
| TONMYA | CYCLOBENZAPRINE HYDROCHLORIDE | Tonix Medicines, Inc. | 6fa59588-ce9b-48cf-8c5f-725a448f8571 | 2026-08-14 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Redpharm Drug | 58e6d82b-52fd-cca3-e063-6294a90a1104 | 2026-08-13 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | REMEDYREPACK INC. | b09ca979-ab6b-441b-a66f-41ca32eae6cb | 2026-08-10 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | REMEDYREPACK INC. | 8bef97d4-1b92-4316-8733-7751d627230f | 2026-08-07 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | REMEDYREPACK INC. | eb2b24b1-2851-440f-9075-b6a123a1fd5c | 2026-08-05 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Cardinal Health 107, LLC | df902d94-9d2b-4139-aebb-3eb6b8b8cd54 | 2026-07-30 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | REMEDYREPACK INC. | f2eb32c3-3da0-4938-9ed9-ea8420450fde | 2026-07-27 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | NuCare Pharmaceuticals,Inc. | 8c66b5ed-f773-0779-e053-2995a90ad1f1 | 2026-07-20 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | TruPharma LLC | 08adc97f-feef-46fb-ac75-f015b4f3a43a | 2026-07-17 | Warnings, Adverse reactions | 828299 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | NuCare Pharmaceuticals, Inc. | 4ee4feec-4590-fa7f-e063-6394a90a5550 | 2026-07-17 | Warnings, Adverse reactions | 0VE05JYS2P |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.